Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection

BACKGROUND: BA.2.12.1, BA.4 and BA.5 subvariants of SARS-CoV-2 variant-of-concern (VOC) Omicron (B.1.1.529) are spreading globally. They demonstrate higher transmissibility and immune escape. OBJECTIVES: Determine BA.2.12.1, BA.4 and BA.5 virus plaque reduction neutralization test (PRNT) antibody ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Samuel SM, Mok, Chris KP, Li, John KC, Ng, Susanna S, Lam, Bosco HS, Jeevan, Trushar, Kandeil, Ahmed, Pekosz, Andrew, Chan, Karl CK, Tsang, Leo CH, Ko, Fanny W, Chen, Chunke, Yiu, Karen, Luk, Leo LH, Chan, Ken KP, Webby, Richard J, Poon, Leo LM, Hui, David SC, Peiris, Malik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428331/
https://www.ncbi.nlm.nih.gov/pubmed/36081282
http://dx.doi.org/10.1016/j.jcv.2022.105273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428331/
https://www.ncbi.nlm.nih.gov/pubmed/36081282
http://dx.doi.org/10.1016/j.jcv.2022.105273

Ejemplares similares